OUR STRATEGY IS BUILT ON INNOVATION, IMPROVING CLINICAL OUTCOMES, IMPROVING PATIENT SAFETY, AND MEETING UNMET MEDICAL NEEDS.
We aim to improve the safety profile and efficacy of molecules that are already on the market, or to make them more patient or user-friendly.
Cosmo has a demonstrated ability to successfully identify unmet medical needs, manage the drug development process and obtain regulatory approval for new products.
Careful cash management has enabled the implementation of our strategic objectives with the Company’s own financial resources.
Our overriding objective is to achieve superior long-term returns for shareholders while minimising risks.
Marketing
Cosmo identifies the best marketing partner for each product and structures its return with a mix of milestones/royalties revenue and/or a share in the revenues and/or stake in the capital of the partner.
Manufacturing
Cosmo relies on its extensive capacity and know-how to be the exclusive supplier on behalf of its partners.
With its vast clinical trial database in GI, Cosmo can develop Artificial Intelligence algorithms to predict the presence of disease, risk of disease progression, and response to treatment; all of which could be supplied to gastroenterologists and endoscopists to deliver higher quality personalized healthcare.
In February 2019, Cosmo acquired Linkverse, a medical imaging, IT medical devices and AI focused company. Linkverse brings expertise in developing machine learning and AI solutions and, to further strengthen its AI capabilities and empower associates to use AI across their business, it has established a new AI Innovation Lab within Cosmo facility in Lainate, Milan, Italy.
Investments in other companies
Cosmo holds stakes in other companies as a result of partnerships and spin-offs including RedHill Biopharma Ltd. (NASDAQ: RDHL), Eagle Pharmaceuticals Inc. (Nasdaq: EGRX) and PAION AG (Frankfurt Stock Exchange, Prime Standard: PA8).